Registered title, quoted from ClinicalTrials.gov
Optimal Application Timing of ADC Drugs for Advanced Breast Cancer
An open trial on breast cancer, registered on ClinicalTrials.gov. Led by Liaoning Cancer Hospital & Institute; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07657130, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 8
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (8 points)Hide the checklist
18 years to 75 years; sex: women only
Registered eligibility fields
Histologically confirmed advanced HER2-negative breast cancer, including IHC 2+/ISH-, IHC 1+/ISH-, and IHC 0/ISH- subtypes;
Inclusion criterion 2
Completed first-line combination chemotherapy for advanced/metastatic disease (specific regimen not restricted), with disease progression (PD) evaluated per RECIST criteria (HR-positive patients must have received at least one line of endocrine therapy);
Inclusion criterion 3
Electrocorticography (ECOG) performance status < 2;
Inclusion criterion 4
ANC ≥ 1.5 × 10⁹/L
Inclusion criterion 7
Platelets ≥ 90 × 10⁹/L
Inclusion criterion 8
Hemoglobin ≥ 90 g/L
Inclusion criterion 9
Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
Inclusion criterion 11
AST or ALT ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver metastases)
Inclusion criterion 12
Creatinine clearance ≥ 60 mL/min
Inclusion criterion 13
No evaluable recurrent or metastatic lesions as defined by RECIST 1.1 criteria;
Exclusion criterion 3
History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix, cutaneous squamous cell carcinoma, or well-controlled localized basal cell carcinoma of the skin;
Exclusion criterion 5
Pregnant or breastfeeding women;
Exclusion criterion 2
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07657130, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Female patients aged 18-75 years;
- Histologically confirmed advanced HER2-negative breast cancer, including IHC 2+/ISH-, IHC 1+/ISH-, and IHC 0/ISH- subtypes;
- Completed first-line combination chemotherapy for advanced/metastatic disease (specific regimen not restricted), with disease progression (PD) evaluated per RECIST criteria (HR-positive patients must have received at least one line of endocrine therapy);
- Electrocorticography (ECOG) performance status < 2;
- Estimated life expectancy ≥ 12 weeks;
- Adequate bone marrow function, defined as:
- ANC ≥ 1.5 × 10⁹/L
- Platelets ≥ 90 × 10⁹/L
- Hemoglobin ≥ 90 g/L
- Adequate hepatic and renal function, defined as:
- Total bilirubin ≤ 1.5 × upper limit of normal (ULN)
- AST or ALT ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver metastases)
- Creatinine clearance ≥ 60 mL/min
- Signed informed consent obtained prior to any study-related procedures or treatments, confirming the patient's willingness to participate and comply with study requirements.
Exclusion Criteria:
- Prior treatment with an ADC after disease recurrence or metastasis;
- Pregnant or breastfeeding women;
- No evaluable recurrent or metastatic lesions as defined by RECIST 1.1 criteria;
- Symptomatic brain parenchymal and/or leptomeningeal metastases with symptoms not adequately controlled by treatment;
- History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix, cutaneous squamous cell carcinoma, or well-controlled localized basal cell carcinoma of the skin;
- Psychiatric disorders or other conditions that may interfere with patient compliance;
- Recent history of serious and uncontrolled systemic diseases, such as clinically significant cardiovascular disease, pulmonary disease, metabolic disorders, or arterial/venous thromboembolic events;
- Concurrent use of other investigational drugs, or participation in another clinical trial within 30 days prior to enrollment;
- Known or suspected allergy to any study drug or its excipients;
- Any other condition that, in the opinion of the investigator, renders the patient unsuitable for participation in this trial.
Quoted from ClinicalTrials.gov, NCT07657130, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07657130, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.